Tharimmune, Inc. THAR
Apr 22, 2026, 12:59 PM EDT
- YTD
- +16.83%
- 1 year
- +207.83%
- Market cap
- 3.11M
- EPS (ttm)
- 61.01
- Shares out
- 1.49M
- P/E ratio
- 0.03
- Forward P/E
- -17.42
- YTD return
- +16.83%
- 1-year return
- +207.83%
- Volume
- 358.85K
- Avg volume
- 1.26M
- Open
- 3.34
- Previous close
- 3.54
- Day's range
- 3.32 – 3.58
- 52-week range
- 1.84 – 8.42
- Beta
- 1.45
- Earnings date
- Mar 21, 2024
2Y -0.89 (-15.24%)
Key statistics
- Enterprise value
- -1.70M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.89
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -5.34M
- Total cash
- 4.77M
- Total debt
- 0
- Return on equity
- -454.53%
- Short % of float
- 4.42%
- 50-day average
- 2.29
- 200-day average
- 3.71
Next earnings
Mar 21, 2024
Expected Mar 21, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | 0.00 | -2.45 | — | — |
| Aug 9, 2024 | Jun 1, 2024 | 0.00 | -2.42 | — | — |
| May 9, 2024 | Mar 1, 2024 | 0.00 | -2.85 | — | — |
| Mar 21, 2024 | Dec 1, 2023 | -0.05 | — | — | — |
| Nov 7, 2023 | Sep 1, 2023 | -18.74 | -41.23 | -22.49 | -120.01% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 6, 2024 | Rodman & Renshaw | init | — | Buy |
About Tharimmune, Inc.
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tharimmune.com
News
Tharimmune Highlights Canton Network Q1 Growth, Tokenomics Shift and Validator Locking in Webinar 
Tharimmune, Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasury Strategy 
Catherine Wood's Strategic Moves: A Closer Look at Tesla Inc's Portfolio Impact 
Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer 
Tharimmune Elects Jill Sommers and William Wiley to Board of Directors 
12 Health Care Stocks Moving In Monday's Pre-Market Session 
Tharimmune Shareholders Approve Directors, Warrant-Linked Share Issuances and 7M Share Plan Boost 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
Tharimmune Announces Expanded Role as Super Validator on Canton Network 
Tharimmune, Inc. And The Canton Network: A Privacy Focused, Asymmetric Bet On Tokenization
Your note
Sign in to keep a note on THAR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| APPAJOSYULA SIREESH | Chief Operating Officer | Purchase | Nov 12, 2024 | 13,372 |
| MILBY RANDY | Chief Executive Officer | Purchase | Dec 18, 2024 | 17,534 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Curi RMB Capital, LLC | 1.22% | 23,620 | 49.37K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.03% | 627 | 1.31K | Sep 29, 2024 |
| JP Morgan Chase & Company | 0.00% | 1 | 2 | Sep 29, 2024 |
| Bank of America Corporation | 0.00% | 9 | 18 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.29% | 5,582 | 11.67K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.07% | 1,350 | 2.82K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.00% | 29 | 60 | Sep 29, 2024 |